Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria.
Arkwright
Peter D
PD
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D001327:Autoimmune Diseases / Q000628:therapy*; D002648:Child; D002908:Chronic Disease; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D008297:Male; D017455:Receptors, IgE / Q000037:antagonists & inhibitors / Q000276:immunology; D000069283:Rituximab; D014581:Urticaria / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; C475664:FCER1A protein, human; D007074:Immunoglobulin G; D007155:Immunologic Factors; D017455:Receptors, IgE; C026408:anti-IgE antibodies; D000069283:Rituximab